Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease

Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease

Background/Objectives: Approximately 25% of the world’s population and more than 60% of patients with type 2 diabetes (T2D) have metabolic-dysfunction-associated steatotic liver disease (MASLD). The association between these pathologies is an important cause of morbidity and mortality in Brazil and...

Full description

Saved in:
Bibliographic Details
Main Authors: Joana D’Arc Matos França de Abreu, Rossana Sousa Azulay, Vandilson Rodrigues, Sterffeson Lamare Lucena de Abreu, Maria da Glória Tavares, Flávia Coelho Mohana Pinheiro, Clariano Pires de Oliveira Neto, Caio Andrade, Alexandre Facundo, Adriana Guimarães Sá, Patrícia Ribeiro Azevedo, Ana Gregória Pereira de Almeida, Debora Camelo de Abreu Costa, Rogério Soares Castro, Marcelo Magalhães, Gilvan Cortês Nascimento, Manuel dos Santos Faria, Adalgisa de Souza Paiva Ferreira
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Biomedicines
Subjects:
metabolic-dysfunction-associated steatotic liver disease
type 2 diabetes mellitus
epidemiology
fibrosis
Online Access:https://www.mdpi.com/2227-9059/12/11/2542
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2227-9059/12/11/2542

Similar Items